Showing 281 - 300 results of 117,004 for search '(( a non decrease ) OR ( 5 ((((we decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.02s Refine Results
  1. 281

    Treatment with anti-JAM-C antibody decreases the severity of antigen-induced arthritis by Gaby Palmer (636)

    Published 2011
    “…Results are expressed as the ratio of technetium-99m (Tc) uptake in the arthritic over the non-inflamed knee. The mean ± standard error of the mean (SEM) of the ratios is shown for anti-JAM-C antibody-treated (= 10 for days 1 and 3, = 6 for day 7; black symbols) and isotype-matched control antibody-treated (= 10 for days 1 and 3, = 5 for day 7; open symbols) mice. …”
  2. 282
  3. 283
  4. 284

    Earlier Migration Timing, Decreasing Phenotypic Variation, and Biocomplexity in Multiple Salmonid Species by Ryan P. Kovach (103840)

    Published 2013
    “…For most salmonid species, life stages, and life histories, freshwater temperature influences migration timing – migration events are occurring earlier in time (mean = 1.7 days earlier per decade over the 3–5 decades), and the number of days over which migration events occur is decreasing (mean = 1.5 days per decade). …”
  5. 285
  6. 286
  7. 287
  8. 288
  9. 289
  10. 290

    Fibrinogen decreases cardiomyocyte contractility through an ICAM-1-dependent mechanism-3 by John H Boyd (88940)

    Published 2011
    “…Group mean absorbance data taken at the plateau fibrinogen concentration (100 μM) demonstrating a strong interaction between the ICAM-1 (8–22) peptide and fibrinogen compared with a small non-specific interaction between the scrambled peptide and fibrinogen. *< 0.05 versus scrambled peptide.…”
  11. 291
  12. 292
  13. 293
  14. 294

    Transforming growth factor (TGF)-β1 induced a robust decrease in S-phase in non-cancer cell strains by Kimberly A Brown (26546)

    Published 2011
    “…Representative histograms are presented illustrating cells that had a robust decrease in S-phase (NMuMG), modest decrease in S-phase (EpH4), and no decrease in S-phase (MDA-MB-436) as a result of TGF-βtreatment. …”
  15. 295
  16. 296
  17. 297
  18. 298
  19. 299
  20. 300